Jump to Main Content

FDA Alerts

FDA Approves Defibrotide Sodium for the Treatment of Adult and Pediatric Patients with Hepatic Veno-Occlusive Disease

The U. S. Food and Drug Administration approved Defitelio (defibrotide sodium, Jazz Pharmaceuticals, Inc.) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).